AAD
  • Meeting Program
  • Registration
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Topics
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Resources
  • Meeting Program
  • Registration
Facebook iconInstagram iconTwitter X icon
Jul 07, 2021

Minimizing iatrogenic burden of atopic dermatitis

Treating AD without creating complications.


Co-directors Raj Chovatiya, MD, PhD, FAAD, and Jonathan I. Silverberg, MD, PhD, MPH, FAAD
Co-directors Raj Chovatiya, MD, PhD, FAAD, and Jonathan I. Silverberg, MD, PhD, MPH, FAAD

Current atopic dermatitis (AD) guidelines employ a step-up treatment approach using optimized basic skin care followed by prescription topical and systemic therapy. The sum of these efforts may result in iatrogenic burden, such as morbidity caused by medical treatment, and may actually worsen the patient burden of AD.

“Iatrogenic burden refers to complications or ill effects that result from medical examination or treatment,” said Raj Chovatiya, MD, PhD, FAAD, assistant professor of dermatology at Northwestern Medicine Feinberg School of Medicine, who will be leading the session “Addressing the Iatrogenic Burden of Atopic Dermatitis,” along with co-director Jonathan I. Silverberg, MD, PhD, MPH, FAAD.  “In the case of AD, this iatrogenic burden involves treatment plans that are more burdensome to patients than their signs and symptoms," Dr. Chovatiya said. "Examples include non-evidence-based care or even well-meaning, evidence-based recommendations that are impractical and detrimental to quality of life.”

Dr. Chovatiya pointed to new research that has expanded the armamentarium of treatments as well as our understanding of the immense patient burden associated with AD and its management. “This session will put it all together and introduce practical, everyday strategies that can improve clinical care and make life better for AD patients,” he said.

During this interactive session, the panel will pinpoint key areas that clinicians can minimize this burden. Walking through the current AD treatment paradigm, the speakers will review a therapeutic strategy consisting of step-up, step-down and maintenance approaches in order to reduce treatment burden and improve quality of life in AD.

“AD can be challenging to manage. However, much of the iatrogenic burden associated with AD can be addressed with effective communication and evidence-based shared decision-making,” Dr. Chovatiya said.

CME Credit 1.00



Pearls: AD decision-making

1.   Listen to your patients. This is the only way to understand the impact of AD and its treatments, which can vary significantly between individuals.

2.    Shared decision-making is key. Work together with your patients to craft a plan that is efficacious, safe, feasible, and aligned with individual goals. One-sided plans are rarely sustainable.

3.    Treatment plans can change, and that’s OK! AD has a heterogeneous course and impact, and therapeutic decisions must be as dynamic as the disease itself.

Interesting Stories
Dermworld June | Smoke and the skin
Presented by AAD
Dermworld June | Smoke and the skin
DermWorld May | Deciding the right time for treatment
Presented by AAD
DermWorld May | Deciding the right time for treatment
DermWorld  January | Scar solutions
Presented by AAD
DermWorld January | Scar solutions
DermWorld February | Glow Up
Presented by AAD
DermWorld February | Glow Up
DermWorld March | Publishing profiteers
Presented by AAD
DermWorld March | Publishing profiteers
DermWorld April | Shedding light on treatments for female pattern hair loss
Presented by AAD
DermWorld April | Shedding light on treatments for female pattern hair loss
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter X icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.